Skip to main content

Table 5 Association between M-, T- and C- scores and clinical outcome in the two treatment arms of the STOP-IgAN trial (available cases analysis)

From: Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores)

   M0 events/ total M1 events/ total T0 events/ total T1/2 events/ total C0 events/ total C1/2 events/ total
Full clinical remissiona SUPc 2/22 (9%) 0/8 (0%) 2/15 (13%) 0/15 (0%) 1/23 (4%) 1/7 (14%)
IMMd 6/26 (23%) 0/9 (0%) 4/24 (17%) 2/11 (18%) 3/22 (14%) 3/13 (23%)
GFR-loss ≥15 ml/min SUP 7/24 (29%) 4/8 (50%) 4/15 (27%) 7/17 (41%) 6/24 (25%) 5/8 (63%)
IMM 7/27 (26%) 5/10 (50%) 7/25 (28%) 5/12 (42%) 10/23 (43%) 2/14 (15%)
ESRDb SUP 3/24 (13%) 1/8 (13%) 1/15 (7%) 3/17 (18%) 1/24 (4%) 3/8 (38%)
IMM 4/27 (15%) 0/10 (0%) 0/25 (0%) 4/12 (33%) 3/23 (13%) 1/14 (7%)
  1. aurinary protein-creatinine ratio < 0.2 g/g and an eGFR decrease of < 5 ml/min/1.73m2
  2. bend-stage renal disease
  3. cpatients under supportive treatment during the 3-year trial phase
  4. dpatients under additional immunosuppression during the 3-year trial phase